Neuroscience News and Research

RSS

Uncovering the science behind generations of mental illness

Sometimes the most interesting way to digest scientific information is within the context of personal experiences. Likewise, the story of someone's personal journey or struggle can take on broader significance when melded with the insights of scientific knowledge.

14 Mar 2012

Elsevier releases NeuroApps: MRI Atlas of Human White Matter

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the release of NeuroApps: MRI Atlas of Human White Matter, the first in a new series of apps created for the iPad.

12 Mar 2012

OPKO Health, Scripps Research partner to commercialize Parkinson's disease compound, SR 3306

The Scripps Research Institute and OPKO Health, Inc. today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

Salk scientists' discovery explains how a class of chemotherapy drugs works

The well-being of living cells requires specialized squads of proteins that maintain order. Degraders chew up worn-out proteins, recyclers wrap up damaged organelles, and-most importantly-DNA repair crews restitch anything that resembles a broken chromosome. If repair is impossible, the crew foreman calls in executioners to annihilate a cell. As unsavory as this last bunch sounds, failure to summon them is one aspect of what makes a cancer cell a cancer cell.

12 Mar 2012

Allon advances into second phase of work in preclinical PD model

Allon Therapeutics Inc. announced today the completion of its first phase of work in a preclinical Parkinson's disease model and advancement into the second phase of work. Both phases are funded by The Michael J. Fox Foundation for Parkinson's Research and carried out by Prof. Marie-Francoise Chesselet's lab at the University of California Los Angeles.

12 Mar 2012

Connect during MS Awareness Week

Multiple sclerosis is a life altering disease that affects each person in a unique and different way. MS destroys connections, divides minds from bodies, pulls people from their lives and away from one another. Therefore, it's only fitting that connections would be its greatest enemy.

12 Mar 2012

Two scientists receive The Brain Prize 2012 for pioneering work on hearing and deafness

The Grete Lundbeck European Brain Research Foundation announced today that The Brain Prize 2012 is jointly awarded to Christine Petit and Karen Steel.

12 Mar 2012

Researchers determine structure of concentrative nucleoside transporter

A team of researchers at Duke University has determined the structure of a key molecule that can carry chemotherapy and anti-viral drugs into cells, which could help to create more effective drugs with fewer effects to healthy tissue.

12 Mar 2012

FDA denies AstraZeneca Citizen Petitions on SEROQUEL labeling

AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.

12 Mar 2012

TSRI, OPKO Health to develop and commercialize SR 3306 for Parkinson's

OPKO Health, Inc. and The Scripps Research Institute today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

Conference highlights studies on metabolism, aging and monarch butterfly migration

The Genetics Society of America's 53rd Annual Drosophila Research Conference, March 7-11 at the Sheraton Chicago Hotel & Towers, will showcase diverse efforts to understand basic biological processes through the easy-to-study fruit fly, Drosophila melanogaster, and other insects.

12 Mar 2012

Methylphenidate may affect learning and memory in children with ADHD

New research with monkeys sheds light on how the drug methylphenidate may affect learning and memory in children with attention deficit hyperactivity disorder.

11 Mar 2012

Study uncovers critical process in understanding degeneration of brain cells sensitive to AD

A research group led by Dr. A. Claudio Cuello of McGill University's Faculty of Medicine, Dept. of Pharmacology and Therapeutics, has uncovered a critical process in understanding the degeneration of brain cells sensitive to Alzheimer's disease.

9 Mar 2012

Single dose of LSD shows promise against alcoholism

Forty years ago, LSD was used in the treatment of alcoholics - with good results. Perhaps it's time to look at it again? In the 1950s, '60s and '70s, researchers in many places in the world experimented with LSD in the treatment of various disorders, including alcoholism. Not all experiments were scientifically tenable by today's standards, but some were.

9 Mar 2012

Researchers identify specific gene linked with throat cancer

Researchers at King's College London and Hiroshima University, Japan, have identified a specific gene linked to throat cancer following a genetic study of a family with 10 members who have developed the condition.

8 Mar 2012

Measuring wellbeing in Huntington’s disease

The new tool, the first Huntington’s disease-specific quality of life instrument of its kind, aims to fully capture the impact of this complex disease on the everyday life of sufferers. By using this new tool to more accurately measure the impact of Huntington’s and also any effect of therapeutic interventions, scientists will be in a better position to evaluate the usefulness of interventions on patients’ everyday quality of life to see if there is actually a practical benefit. It is hoped that in this way, this tool will lead to more effective treatments.

8 Mar 2012

CB2 receptor involved in regulating impulsive behaviour

A new study lead by the Neuroscience Institute of Alicante reveals how manipulating the endocannabinoid system can modulate high levels of impulsivity. This is the main problem in psychiatric illnesses such a schizophrenia, bipolar disorder and substance abuse.

8 Mar 2012